Stephens Consulting’s Rocket Pharmaceuticals RCKT Stock Holding History

Stephens Consulting’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50	Closed	-$334	–	1812
2025 Q1	$334	Buy	+50	New	+$494	﹤0.01%	1410

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Stephens Consulting's RCKT Position: Q2 2025 in Review

Stephens Consulting sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 50 shares — an estimated $334 sold.

Stephens Consulting first reported a position in RCKT in Q1 2025 and held it in 1 quarter. The position peaked at $334 in Q1 2025. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

Stephens Consulting reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 50 Rocket Pharmaceuticals shares in Q2 2025, an estimated $334.
Stephens Consulting first reported a position in Rocket Pharmaceuticals in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Rocket Pharmaceuticals position peaked at $334 in Q1 2025.
196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.